贝匹罗韦森在人类免疫缺陷病毒和慢性乙型肝炎病毒感染参与者中的研究(B-Focus) (B-Focus)
一项多中心、随机、双盲、安慰剂对照研究,旨在评估贝匹罗韦森治疗人类免疫缺陷病毒和慢性乙型肝炎病毒感染患者抗逆转录病毒治疗的有效性和安全性
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Ontario
-
Ottawa、Ontario、加拿大、K1H 8L6
- GSK Investigational Site
-
Toronto、Ontario、加拿大、M5G 1K2
- GSK Investigational Site
-
-
Quebec
-
Montreal、Quebec、加拿大、H2L 4P9
- GSK Investigational Site
-
Montreal、Quebec、加拿大、H4A 3J1
- GSK Investigational Site
-
Québec、Quebec、加拿大、G1V 4G2
- GSK Investigational Site
-
-
-
-
-
Ekurhuleni、南非、1459
- GSK Investigational Site
-
Johannesburg、南非、2092
- GSK Investigational Site
-
-
KwaZulu-Natal
-
Durban、KwaZulu-Natal、南非、4052
- GSK Investigational Site
-
-
-
-
-
Banchiau Taipei、台湾、220
- GSK Investigational Site
-
Kaohsiung City、台湾、813
- GSK Investigational Site
-
-
-
-
-
Aracaju、巴西、49060-010
- GSK Investigational Site
-
Campinas、巴西、13034-685
- GSK Investigational Site
-
Curitiba、巴西、80810-050
- GSK Investigational Site
-
Manaus、巴西、69040-000
- GSK Investigational Site
-
Salvador、巴西、40110-060
- GSK Investigational Site
-
São Paulo、巴西、04121-000
- GSK Investigational Site
-
-
-
-
-
Genova、意大利、16132
- GSK Investigational Site
-
Milan、意大利、20157
- GSK Investigational Site
-
Milan、意大利、20162
- GSK Investigational Site
-
Naples、意大利、80131
- GSK Investigational Site
-
Roma、意大利、00153
- GSK Investigational Site
-
Sassari、意大利、07100
- GSK Investigational Site
-
-
-
-
-
Marseille、法国、13003
- GSK Investigational Site
-
Melun、法国、77000
- GSK Investigational Site
-
Montpellier、法国、34295
- GSK Investigational Site
-
Nantes、法国、44093
- GSK Investigational Site
-
Paris、法国、75018
- GSK Investigational Site
-
Paris、法国、75012
- GSK Investigational Site
-
-
-
-
California
-
Bakersfield、California、美国、93301
- GSK Investigational Site
-
San Francisco、California、美国、94115
- GSK Investigational Site
-
-
Florida
-
Orlando、Florida、美国、32803-1851
- GSK Investigational Site
-
West Palm Beach、Florida、美国、33409
- GSK Investigational Site
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55415
- GSK Investigational Site
-
-
New Jersey
-
Hillsborough、New Jersey、美国、08844
- GSK Investigational Site
-
-
-
-
-
Bristol Avon、英国、BS10 5NB
- GSK Investigational Site
-
London、英国、E1 1BB
- GSK Investigational Site
-
London、英国、SE5 9RS
- GSK Investigational Site
-
London、英国、NW3 2QG
- GSK Investigational Site
-
-
-
-
-
Barcelona、西班牙、08036
- GSK Investigational Site
-
Córdoba、西班牙、14004
- GSK Investigational Site
-
Madrid、西班牙、28041
- GSK Investigational Site
-
Madrid、西班牙、28040
- GSK Investigational Site
-
Madrid、西班牙、28046
- GSK Investigational Site
-
Madrid、西班牙、28031
- GSK Investigational Site
-
-
-
-
-
Almagro、阿根廷、C1427CEA
- GSK Investigational Site
-
Buenos Aires、阿根廷、1023
- GSK Investigational Site
-
Buenos Aires、阿根廷、C1425AGC
- GSK Investigational Site
-
Buenos Aires、阿根廷、C1181ACI
- GSK Investigational Site
-
La Plata、阿根廷、B1900AVG
- GSK Investigational Site
-
Rosario、阿根廷、S2002KDR
- GSK Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Documented chronic hepatitis B virus (HBV) infection and documented human immunodeficiency virus (HIV)-1 infection greater than equal to (>=) 12 months prior to Screening.
-
Must be on uninterrupted antiretroviral therapy (ART) containing at least tenofovir disoproxil (TDF) or tenofovir alafenamide (TAF) plus lamivudine (3TC) or emtricitabine (FTC) for greater than (>)12 months, with no planned changes to the stable regimen over the duration of the study.
o Switch in ART is permitted >=6 months prior to Screening for reasons not related to loss of HIV or HBV control (e.g., change in formulary, tolerability, side effects).
-
Documented evidence of at least 2 plasma HIV-1 ribonucleic acid (RNA) measurements less than (<) 50 copies per milliliter (copies/mL) are required in the 12 months prior to Screening: 1 within 6 to 12 months prior to Screening and 1 within 6 months prior to Screening.
-
Plasma or serum HBV deoxyribonucleic acid (DNA) concentration must be adequately suppressed, defined as plasma or serum HBV DNA <90 international units per milliliter (IU/mL).
-
Plasma or serum HBsAg concentration >100 IU/mL and <=3000 IU/mL.
-
Plasma HIV-1 RNA concentration must be undetectable, defined as plasma HIV 1 RNA <50 copies/mL.
-
Cluster of differentiation 4 (CD4) count >=350 cells per cubic millimeter (cells/mm^3).
-
Alanine aminotransferase (ALT) <=2 times upper limit of normal (ULN).
Exclusion Criteria:
-
History of or suspected liver cirrhosis and/or evidence of cirrhosis.
-
Diagnosed or suspected hepatocellular carcinoma (HCC).
-
History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
-
Coinfection with:
-
Hepatitis C virus (HCV) with positive HCV antibody and detectable HCV RNA at Screening.
I. HCV treatment should have completed >12 months prior to Screening.
-
Hepatitis D virus (HDV) defined as positive or equivocal HDV antibody regardless of HDV RNA level.
-
-
Clinically significant abnormalities, aside from HIV-1 infection and chronic HBV infection in medical history (e.g., moderate severe liver disease other than chronic HBV/HIV, acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis coagulopathy) or clinically significant physical examination findings.
-
Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded unless they complete treatment during the Screening period and 7 days prior to randomization.
-
History of malignancy within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
-
History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause), current or history of an autoimmune condition or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
-
Participants who in the investigator's judgment, have a significant risk of suicide or self-harm.
-
Alcohol or drug abuse/dependence
-
Currently taking, or took within 3 months of Screening, any immunosuppressing drugs (e.g., prednisone), other than a short course of therapy (<=2 weeks) or topical/inhaled steroid use.
-
Participants to whom immunosuppressive treatment, including therapeutic doses of steroids, is contraindicated should not be considered for enrolment in the study.
-
Currently taking, or has taken within 12 months of Screening, any interferon containing therapy.
-
Participants requiring anti coagulation therapies (e.g., warfarin, Factor Xa inhibitors) or anti platelet agents (including but not limited to clopidogrel or aspirin) unless treatment can safely be discontinued throughout duration of study intervention, by the discretion of the investigator. Occasional use is permitted.
-
Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
-
Prior treatment with any oligonucleotide or small interfering ribonucleic acid (siRNA) within 12 months prior to the first dosing day.
-
Prior treatment with bepirovirsen.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Participants receiving Bepirovirsen
Participants will receive bepirovirsen. |
Bepirovirsen will be administered. |
|
安慰剂比较:Participants receiving Placebo
Participants will receive placebo. |
Placebo will be administered. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medication
大体时间:At study week 60
|
HBV virologic response defined as HBV surface antigen (HBsAg) not detected and HBV deoxyribonucleic acid (DNA) less than (<) lower limit of quantification (LLOQ). |
At study week 60
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of participants achieving HBV virologic response at the scheduled end of study treatment in absence of rescue medication
大体时间:At study week 24
|
HBV virologic response defined as HBsAg not detected and HBV DNA <LLOQ. |
At study week 24
|
合作者和调查者
调查人员
- 研究主任:GSK Clinical Trials、GlaxoSmithKline
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 219231
- 2023-509588-25 (其他标识符:EU CT Number)
- 2023 (美国 NIH 拨款/合同)
- 2023-509588-25-00 (注册表标识符:CTIS (EU))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD 共享时间框架
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD 共享访问标准
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.